Company intelligence / Profile preview

Nivalis Therapeutics

Boulder, CO, United Statess202.q4cdn.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Nivalis Therapeutics was developing disease-modifying therapies for patients with cystic fibrosis. The company's drug candidates included N-1785, N-1861, N-6022, S-Nitrosoglutathione, and Cavosonstat, targeting conditions like cystic fibrosis and asthma.

Therapeutic areas: Pulmonology
Modalities: Small molecule drug
Industry: Biotech

Beyond the preview

Go deeper on Nivalis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nivalis Therapeutics.

Explore the full profile